Using genetic and neuroimaging correlates of early psychosis to investigate the underlying mechanisms of the disorder.

本项目的目的是寻找遗传和神经影像学预测治疗反应的抗精神病药物（目的1）和大麻二酚（目的2）在首次发作的精神病患者。通过招募首次发病的患者，我们希望在疾病的早期阶段找到治疗反应的预测因子。抗精神病药物耐药性与遗传和脑指标差异相关（Vita et al. 2019）。我将检验这一假设，即这些因素也会影响抗精神病药和大麻二酚的反应。

The aim of this project is to find genetic and neuroimaging predictors of treatment response both to antipsychotic medication (Aim 1) and to cannabidiol (Aim 2) in patients with first episode psychosis. By recruiting first episode patients we hope to find predictors of treatment response in early stages of the disorder. Resistance to antipsychotic medication is associated with both genetic and brain metric differences (Vita et al. 2019). I will test the hypothesis that these factors also influence the response to antipsychotics and to cannabidiol.